# Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals

> **NCT01293123** · NA · TERMINATED · sponsor: **University of California, San Diego** · enrollment: 2 (actual)

## Conditions studied

- HIV

## Interventions

- **DRUG:** Raltegravir
- **DRUG:** Efavirenz

## Key facts

- **NCT ID:** NCT01293123
- **Lead sponsor:** University of California, San Diego
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-12
- **Primary completion:** 2013-06
- **Final completion:** 2013-12
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Did not meet enrollment goals
- **Last updated:** 2019-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01293123

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01293123, "Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01293123. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*